Anida Pharma, Inc. is a biopharmaceutical company developing new therapies for orphan neurological indications with a focus on pediatric indications: retinopathy of prematurity (ROP), brain injury of the newborn (hypoxic-ischemic encephalopathy; HIE), and drug-induced hearing loss. Anida also has a program for the treatment of amyotrophic lateral sclerosis (ALS; Lou Gehrig disease).

Anida is developing first-in-class therapeutics and will bring to the clinic compounds that activate the body's own mechanisms to regulate inflammation, cell survival and promote tissue repair. By activating the body’s own pathways they offer the potential of being highly efficacious and also exceptionally safe.

Our targeted indications:The retinopathy that may develop in the prematurely born baby is a major global issue with tens of thousands of children every year suffering major vision loss and with many thousand becoming legally blind.

HIE occurs in 4-6/1000 newborns with a major risk of cerebral palsy, chronic epilepsy, hearing and vision loss, and cognitive deficits throughout later life.

No therapy exists to prevent or restore loss of hearing that will be permanent, a particular concern for pediatric patients in various cancer and infectious disease regimens.

Existing therapies for slowing of disease progression in ALS at best have a modest effect and new therapies are urgently needed for a disease with an average remaining lifespan as short as 3.5 years from the time of diagnosis.